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new class of compounds licenced for the treatment of immune
thrombocytopenic purpura. They are currently being studied for
patients with thrombopenia in advanced liver disease or under
therapy for hepatitis C. There are indications that the risk for
development of portal vein thrombosis in patients with advanced
liver cirrhosis might be increased under therapy with thrombo-
poietin receptor agonists. We report a case of a patient with Child
class B liver cirrhosis with concurrent immune thrombocytopenic
purpura that developed portal vein thrombosis under therapy
with the thrombopoietin receptor agonist romiplostim.
Methods: A 50-year-old woman with hepatitis C virus associated
immune thrombocytopenic purpura and Child class B liver
cirrhosis presented in our emergency with rapidly evolving
hydropic decompensation and general malaise. For immune
thrombocytopenic purpura, the patient was started on the
thrombopoietin receptor agonist romiplostim nine months ago.
Results: During hospitalization, the platelet count was measured
above 330,000/ll and partial portal vein thrombosis was diag-
nosed by imaging studies. The thrombotic event was assumed
to be associated with the romiplostim treatment for immune
thrombocytopenic purpura via excessive elevation of platelet
count. After anticoagulation with heparin and cessation of romi-
plostim treatment, complete recanalisation of the portal vein was
achieved.
Conclusions:We conclude that romiplostim should be used with
precaution in patients with hepatitis C-associated immune
thrombocytopenic purpura and advanced liver cirrhosis as the
risk for thrombotic complications may increase signiﬁcantly.
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GP, glycoprotein.A 50-year-old woman with Child class B liver cirrhosis due to
chronic hepatitis C was admitted to the hospital in June 2010
with rapidly evolving hydropic decompensation and general mal-
aise. The patient was on the waiting list for orthotopic liver trans-
plantation and had a Model for End-Stage Liver Disease (MELD)
score of 20. Abdominal ultrasound examination showed large
amounts of ascitic ﬂuid and a thrombus that had emerged in
the extrahepatic portal vein and which obstructed approximately
two third of the veins lumen. By doppler sonography, portal vein
peak-ﬂow was measured to be 22 cm/s. Liver veins showed no
abnormalities. The diagnosis was conﬁrmed by computed tomog-
raphy which showed a localized thrombosis at the intersection of
the superior mesenteric vein into the portal vein (Figs. 1 and 2).
Previous abdominal CT scans and regularly performed abdominal
ultrasound examinations had never documented an obstruction
of the portal vein so that it was assumed to be a recent event.
The patient had HCV-associated immune thrombocytopenic
purpura (ITP) and treatment with the thrombopoitin receptor
agonist (TRA) romiplostim was started nine months ago. ITP
had been diagnosed in March 2009 by the detection of IgM and
IgG antibodies by platelet immunoﬂuorescence test (PIFT). The
antibodies were speciﬁed by simultaneous analysis of speciﬁc
platelet antibodies (SASPA) such as IgG antibodies against GP
(glycoprotein) IIb/IIIA, IX, Ia/IIA, CD32, CD62p, CD9, GPV,
CD109, CD31, CD49e, CD36, and HLA-class I-attributes and IgM
antibodies against GP IX. Pseudothrombocytopenia was excluded
previously by blood smear examination. Bone marrow aspiration
had shown increased megakaryopoiesis. As the patient experi-
enced bleeding from esophageal varices in the past, coexisting
ITP was considered as a major risk factor for re-bleeding although
band ligation was performed previously and the patient was on
prophylactic propranolol therapy. Therefore, ITP was treated by
pulse therapy with glucocorticosteroids 2 mg/kg but no signiﬁ-
cant increase in platelet count could be observed. Glucocorticos-
teroids were ultimately stopped as the patient developed
deterioration of blood glucose levels and hepatic encephalopathy.
Since platelets dropped below 20,000/ll repeatedly, treatment
with the TRA romiplostim 500 lg/week subcutaneously was ini-
tiated. Romiplostim is approved for patients with ITP in which
steroids are not successful and in which splenectomy is not11 vol. 55 j 229–232
Fig. 1. The coronal and sagital view of a contrast enhanced CT in a 50-year-old female patient shows partial obstruction of the portal vein. The white arrow indicates
narrowing and partial obstruction due to a huge thrombosis located in the extrahepatic portal vein.
Case Reportrecommended. At that time point, the patient had a Child class B
cirrhosis with a MELD score of 16 without clinical signs of hepatic
encephalopathy or hydropic decompensation. Weekly romiplo-
stim injections resulted in a rapid increase in platelet count over
50,000/ll and were continued until hospital admission in June
2010.
Review of the platelet count during hospitalization revealed a
peak of 331,000/ll whereas platelet count ranged between
50,000/ll and 100,000/ll during several weeks before admission
(Fig. 3). Hence, coincidence of exceeding increase in platelet
count and onset of portal vein thrombosis suggests a causative
role of romiplostim leading to immediate discontinuation of
romiplostim treatment. Thrombophilia screening including anti-
phospholipid antibodies, factor II/V mutations and Jak 2 genotyp-
ing did not show any abnormalities. Continuous intravenous
administration of unfractionated heparin was initiated and the
clinical condition of the patient improved constantly. The beneﬁ-
cial antithrombotic effect of heparin treatment was evaluated by
intra-arterial digital subtraction angiography (DSA) of the celiac230 Journal of Hepatology 201trunk and superior mesenteric arteries nine days later. Fortu-
nately, complete recanalization of the portal vein was achieved
(Fig. 4). Celiac trunk and inferior vena cava were shown to be free
of thrombotic material. The patient was discharged two weeks
after the diagnosis of portal vein thrombosis and low molecular
weight heparin was administered subcutaneously thereafter.
Finally, the patient received a liver graft in August 2010. Histo-
logic examination of the patient’s explanted liver revealed
advanced cirrhosis without evidence of hepatocellular carcinoma.Discussion
Chronic HCV infection is associated with a variety of extrahepatic
manifestations including lymphoproliferative hematologic dis-
eases as well as a wide range of immune-related disorders
[1,2]. Recent reports emphasize that the incidence rate of ITP in
patients with chronic hepatitis C is higher than previously1 vol. 55 j 229–232
Fig. 2. The 3D reconstruction of the contrast enhanced CT shows the region of
partial obstruction of the portal vein. The reconstruction was done as an
attempt to localize the exact level of obstruction which was the region of
intersection of the superior mesenteric vein into the portal vein.
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Fig. 3. Development of platelet count from diagnosis to start of romiplostim
therapy and detection of portal vein thrombosis.
Fig. 4. Digital subtraction angiography of the patient after cessation of
romiplostim and treatment with heparin for 9 days. The vascular anatomy of
the inferior mesenteric artery and completely recanalized portal venous system
are shown. Notice the large portal vein due to portal hypertension and the
absence of the huge thrombosis previously shown on the CT.
JOURNAL OF HEPATOLOGYexpected [3]. ITP can either occur de novo as primary ITP or sec-
ondary due to other underlying conditions, such as pharmaco-
therapy, autoimmune diseases, or chronic viral infections
including HCV [4]. About 20% of ITP patients have serologic evi-
dence of HCV infection. Thus, routine screening for HCV in
patients with ITP is now recommended [5].
ITP is characterized by thrombocytopenia (<100,000/ll) due
to the formation of autoantibodies against platelet surface anti-
gens. Pathophysiology involves exceeding platelet destruction
due to accelerated elimination of antibody-coated platelets by
macrophages and dendritic cells in the spleen. Additionally, auto-
antibodies seem to directly impair platelet production in the
bone marrow. Furthermore the thrombopoietin blood level inJournal of Hepatology 201ITP patients seems to be low in relation to the depressed platelet
numbers (relative thrombopoietin deﬁciency) [6]. In patients
with liver disease, platelet count may be diminished further by
exceeding sequestration of platelets in the enlarged spleen.
To allow the diagnosis of ITP, a low platelet count is obligatory
(<100,000/ll) and other secondary causes should be excluded. In
60–80% of cases platelet-bound antibodies can be detected [7]
and speciﬁed as antibodies against platelet surface antigens
(e.g. GP IIb/IIIa, GP Ib/IX, GP Ia/IIa) with highly sensitive and spe-
ciﬁc tests. The detection of speciﬁc platelet bound antibodies con-
ﬁrms the immunologic cause for the low platelet count, but
determination between primary and secondary ITP is not possi-
ble. Bone marrow aspiration shows activation of megakaryopoie-
sis [8].
The therapeutic strategy is determined by bleeding complica-
tions and platelet count. ITP patients with platelet counts over
30,000/ll without bleeding complications do not require therapy,
whereas ITP patients with serious bleedings (requiring transfu-
sion) should receive treatment regardless of the number of plate-
lets. Due to complications of portal hypertension, the risk of
bleeding in our patient was considered even higher as in other-
wise healthy individuals with ITP. First line therapy for ITP are
steroids given in a dosage of 1–4 mg/kg (predniso[lo]ne) for
1–2 weeks and subsequent dose reduction or alternatively, dexa-
methasone 40 mg/d for 4 days repeatedly every 14–28 days. Ini-
tial responses are over 70%, but sustained response is reached in
10–50% only. In the acute bleeding situation iv immunoglobulins
are added to the therapy regime. The second line therapy
includes splenectomy with a sustained response in about 60%
of patients [9].
Newer approaches for refractory ITP therapy include, ritux-
imab, a CD20 receptor antibody that alters B cell response and
antibody formation, thus leading to a response in 30–50% of
patients. Nevertheless it is not yet approved for ITP [9].1 vol. 55 j 229–232 231
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The idea that thrombocytopenia is not singularly caused by
increased platelet destruction but also by impaired platelet for-
mation and relative thrombopoietin deﬁciency led to the devel-
opment of agents that directly stimulate the thrombopoietin
receptor. Two drugs have been approved for the treatment of
refractory ITP: (1) eltrombopag, an organic molecule adminis-
tered orally once daily, and (2) romiplostim, a protein of 60 kDa
where the thrombopoietin binding domain is linked to the Fc
portion of IgG, which is administered by subcutaneous injection
once a week [10]. In the ﬁrst randomized controlled phase III
study about 80% of ITP patients showed a platelet response under
romiplostim treatment in comparison to less than 10% in the pla-
cebo group [10]. Comparable results were seen in a recent phase
III study testing eltrombopag [11]. In August 2008 romiplostim
was approved in the US for patients with ITP lacking sufﬁcient
response to other treatments. The most frequent side effects
associated with romiplostim treatment are headache, arthralgia,
and myalgia. After abrupt termination of treatment, the platelet
count can temporarily drop under the initial value. In some
patients an increase in bone marrow reticulin has been reported.
That is why bone marrow examination of treated patients before
and during therapy should be considered [12].
Thrombotic events under eltrombopag and romiplostim have
been reported but clear evidence of an increased risk during
romiplostim therapy is lacking [12]. However, recently there
has been an alarming communication about an increased number
of portal vein thromboses in patients with advanced liver disease
receiving eltrombopag in a randomized controlled trial [http://
www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlert-
sforHumanMedicalProducts/ucm211796.htm). Since thrombocy-
topenia in patients with advanced liver disease is common and
platelet administration may be necessary prior to invasive proce-
dures, this study was initiated to evaluate the efﬁcacy of
eltrombopag in cirrhotic patients. Eltrombopag was administered
14 days before an elective invasive procedure. In May 2010, a
drug alert was issued and the study was terminated by the spon-
sor as portal vein thrombosis had been detected in 4% of patients
receiving eltrombopag in comparison to only 1% in the placebo
arm. All except one patient experienced the portal vein thrombo-
sis at platelet counts above 200,000/ll.
The data are in line with the case described for our patient
since a high platelet count coincided with the development of
portal vein thrombosis. Patients with liver disease per se have
an increased risk for portal vein thrombosis. The prevalence is
1% in early stages of liver cirrhosis and 30% in candidates for liver
transplantation [13]. It can be assumed that treatment with TRAs
is an additional risk factor for portal vein thrombosis, at least, if
an uncontrolled elevation of the platelet numbers in patients
with precipitating risk factors like advanced liver disease is
induced.
Currently, new indications for TRAs in patients with liver dis-
ease are being investigated.
In patients with advanced chronic hepatitis C (including Child
class A) in whom platelet counts below 90,000/ll to 100,000/ll
are present, treatment with pegylated interferon alfa2a or 2b
should be initiated with caution according to the package inserts.
Furthermore, treatment with pegylated interferon alfa and
ribavirin frequently requires dose reductions due to bone marrow
toxicity which negatively affects sustained virologic response232 Journal of Hepatology 201rates [14]. Early clinical trials have been published or are cur-
rently under way to evaluate the efﬁcacy of eltrombopag and
romiplostim to enable antiviral treatment in patients with
advanced chronic hepatitis C and thrombocytopenia [15], (and
www.clinicaltrials.gov). So far, no increased frequency of throm-
botic events has been reported to our knowledge in patients with
compensated Child class A liver cirrhosis, however, the present
case illustrates the potential risks.
In conclusion, treatment with the TRA romiplostim for ITP was
associated with portal vein thrombosis in our patient with
advanced Child class B liver cirrhosis due to chronic hepatitis C.
A careful risk-beneﬁt analysis is recommended prior to the initi-
ation of TRA therapy in patients with advanced liver disease and
platelet counts should be monitored regularly in short intervals.Conﬂict of interest
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